| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.21 | 6e-06 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.12 | 8e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.18 | 9e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.21 | 0.0005 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.19 | 0.001 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.18 | 0.002 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | 0.087 | 0.006 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.15 | 0.007 |